Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA
The US FDA has accepted a Biologics License Application and granted Priority Review for its RSV older adult vaccine candidate.
-
GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia of CKD
Daprodustat was studied in the ASCEND phase III clinical trial programme.
-
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets.
-
US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W
The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option.
-
GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022
GSK will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for IDWeek 2022.
-
US FDA approves Boostrix for immunization during pregnancy for the prevention of whooping cough in newborn infants
The FDA has approved Boostrix for immunization during the third trimester of pregnancy to help prevent pertussis (whooping cough).
-
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA phase III trial in recurrent ovarian cancer
The US FDA will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss overall survival data from the Nova trial
-
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr
-
GSK announces update on US FDA regulatory review of daprodustat in anaemia of chronic kidney disease
GSK today announced that the US FDA will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review daprodustat
-
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial
-
Statement: Zantac (ranitidine) U.S. litigation
Statement regarding U.S. Zantac (ranitidine) litigation
-
GSK completes acquisition of Affinivax, Inc.
GSK today announced it has completed the acquisition of Affinivax, Inc, a clinical-stage biopharmaceutical company based in Cambridge.
-
Statement: Zantac (ranitidine) litigation
Response to recent speculative commentary regarding U.S. Zantac litigation
-
GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
Insights revealed sustained decline of recommended adult immunizations, excluding flu vaccinations, across the US during the pandemic
-
GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis
-
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK begins shipping FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT
-
GSK completes acquisition of Sierra Oncology
A California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer
-
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
Inaugural grant awarded to the HealthTree Foundation, a non-profit organization who will address disparities in care in multiple myeloma
-
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
GSK and Sanofi announce positive data from their vaccine trial
-
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
